Coherus BioSciences (NASDAQ:CHRS – Free Report) had its price target lowered by Robert W. Baird from $11.00 to $9.00 in a research note released on Tuesday, Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Other equities research analysts have also recently issued research reports about the stock. StockNews.com assumed […]
Coherus BioSciences (NASDAQ:CHRS – Free Report) had its price objective trimmed by Robert W. Baird from $11.00 to $9.00 in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the company. […]
Coherus BioSciences (NASDAQ:CHRS – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $13.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 496.33% from the company’s current […]
Citigroup Inc. lowered its position in Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) by 41.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 508,103 shares of the biotechnology company’s stock after selling 361,210 shares during the quarter. Citigroup Inc. owned 0.54% […]